Trasplante de microbiota fecal como alternativa de tratamiento por infecciones de clostridoides difficile
Fecal microbiota transplantation as a treatment alternative for clostridoides difficile infectionsContenido principal del artículo
La infección por Clostridioides difficile es una amenaza para la salud pública, está asociada a la atención médica, cuya complicación más frecuente es la infección recurrente, con tasas de hasta el 60% después del tercer episodio. Las opciones de tratamiento para la recurrencia de esta infección son limitadas. Una gran paradoja es tratar una infección asociada a antibióticos con más antibióticos, por ello, la piedra angular en el manejo de esta infección es la restauración de la microbiota intestinal mediante el trasplante de microbiota fecal. Objetivo. Determinar la eficacia y seguridad del trasplante de microbiota fecal para el tratamiento de la infección recurrente por Clostridioides difficile. Metodología. Se realizó una revisión bibliográfica narrativa de la literatura científica en las bases de datos PubMed y Cochrane Library empleando los Descriptores en Ciencias de la Salud (DeCS) y Medical Subject Headings (MeSH), junto con los operadores booleanos “AND/Y”, “OR/O”; donde se recopilaron los estudios que cumplieron con los criterios de inclusión. Conclusión. Se concluyó que el trasplante de microbiota fecal en la infección recurrente por Clostridioides difficile es un tratamiento eficaz y seguro, con eventos adversos mínimos, aunque la seguridad a largo plazo no está bien establecida.
Clostridioides difficile infection is a public health threat, is associated with health care, the most common complication of which is recurrent infection, with rates of up to 60% after the third episode. Treatment options for recurrence of this infection are limited. A great paradox is to treat an antibiotic-associated infection with more antibiotics; therefore, the cornerstone in the management of this infection is the restoration of the intestinal microbiota by fecal microbiota transplantation. Objective. To determine the efficacy and safety of fecal microbiota transplantation for the treatment of recurrent Clostridioides difficile infection. Methodology. A narrative bibliographic review of the scientific literature was carried out in the PubMed and Cochrane Library databases using the Health Sciences Descriptors (DeCS) and Medical Subject Headings (MeSH), together with the Boolean operators "AND/Y", "OR/O"; where the studies that met the inclusion criteria were collected. Conclusion. It was concluded that fecal microbiota transplantation in recurrent Clostridioides difficile infection is an effective and safe treatment, with minimal adverse events, although long-term safety is not well established.
Descargas
Detalles del artículo
Zhu D, Sorg JA, Sun X. Clostridioides difficile Biology: Sporulation, Germination, and Corresponding Therapies for C. difficile Infection. Frontiers in Cellular and Infection Microbiology [Internet]. 2018 [citado 21 de septiembre de 2022];8. Disponible en: https://www.frontiersin.org/articles/10.3389/fcimb.2018.00029/full
Finn E, Andersson FL, Madin-Warburton M. Burden of Clostridioides difficile infection (CDI) - a systematic review of the epidemiology of primary and recurrent CDI. BMC Infect Dis. 2021;21:456. Disponible en: https://rdcu.be/c0TA1
Balsells E, Shi T, Leese C, Lyell I, Burrows J, Wiuff C, et al. Global burden of Clostridium difficile infections: a systematic review and meta-analysis. J Glob Health. 2019;9(1):010407. Disponible en: 10.7189/jogh.09.010407
Cho JM, Pardi DS, Khanna S. Update on Treatment of Clostridioides difficile Infection. Mayo Clinic Proceedings. 2020;95(4):758-69. Disponible en: https://doi.org/10.1016/j.mayocp.2019.08.006
Popovich KJ, Calfee DP, Patel PK, Lassiter S, Rolle AJ, Hung L, et al. The Centers for Disease Control and Prevention STRIVE Initiative: Construction of a National Program to Reduce Health Care–Associated Infections at the Local Level. Ann Intern Med. 2019;171(7):S2-6. Disponible en: 10.7326/M18-3529
Khanna S, Sims M, Louie TJ, Fischer M, LaPlante K, Allegretti J, et al. SER-109: An Oral Investigational Microbiome Therapeutic for Patients with Recurrent Clostridioides difficile Infection (rCDI). Antibiotics. 2022;11(9):1234. Disponible en: 10.3390/antibiotics11091234
Chilton CH, Pickering DS, Freeman J. Microbiologic factors affecting Clostridium difficile recurrence. Clinical Microbiology and Infection. 2018;24(5):476-82. Disponible en: 10.1016/j.cmi.2017.11.017
Khanna S. Microbiota restoration for recurrent Clostridioides difficile: Getting one step closer every day! Journal of Internal Medicine. 2021;290(2):294-309. Disponible en: 10.1111/joim.13290
McDonald LC, Gerding DN, Johnson S, Bakken JS, Carroll KC, Coffin SE, et al. Clinical Practice Guidelines for Clostridium difficile Infection in Adults and Children: 2017 Update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA). Clin Infect Dis. 2018;66(7):e1-48. Disponible en: 10.1093/cid/cix1085
Quera R, Ibáñez P, Simian D, Rivera D, Acuña G, Espinoza R, et al. Experiencia del trasplante de microbiota fecal a través de colonoscopía en el tratamiento de la infección por Clostridium difficile recurrente. Revista médica de Chile. 2018;146(8):823-30. Disponible en: http://dx.doi.org/10.4067/s0034-98872018000800823
Waldbaum C, Antelo P, Sordá J. Infección severa y complicada por Clostridium difficile resuelta con trasplante de microbiota. Acta Gastroenterol Latinoam. 2017;47(3):211-5. Disponible en: https://www.redalyc.org/pdf/1993/199352918009.pdf
Prehn J van, Reigadas E, Vogelzang EH, Bouza E, Hristea A, Guery B, et al. European Society of Clinical Microbiology and Infectious Diseases: 2021 update on the treatment guidance document for Clostridioides difficile infection in adults. Clinical Microbiology and Infection. 2021;27:S1-21. Disponible en: 10.1016/j.cmi.2021.09.038
Song JH, Kim YS. Recurrent Clostridium difficile Infection: Risk Factors, Treatment, and Prevention. Gut Liver. 2019;13(1):16-24. Disponible en: 10.5009/gnl18071
Webb BJ, Subramanian A, Lopansri B, Goodman B, Jones PB, Ferraro J, et al. Antibiotic Exposure and Risk for Hospital-Associated Clostridioides difficile Infection. Antimicrobial Agents and Chemotherapy. 2020;64(4):e02169-19. Disponible en: 10.1128/AAC.02169-19
Dumic I, Nordin T, Jecmenica M, Stojkovic Lalosevic M, Milosavljevic T, Milovanovic T. Gastrointestinal Tract Disorders in Older Age. Flisiak R, editor. Canadian Journal of Gastroenterology and Hepatology. 2019;2019:6757524. Disponible en: 10.1155/2019/6757524
Anjewierden S, Han Z, Brown AM, Donskey CJ, Deshpande A. Risk factors for Clostridioides difficile colonization among hospitalized adults: A meta-analysis and systematic review. Infect Control Hosp Epidemiol. 2021;42(5):565-72. Disponible en: 10.1017/ice.2020.1236
Mehta P, Nahass RG, Brunetti L. Acid Suppression Medications During Hospitalization as a Risk Factor for Recurrence of Clostridioides difficile Infection: Systematic Review and Meta-analysis. Clin Infect Dis. 2020;73(1):e62-8. Disponible en: 10.1093/cid/ciaa545
Kelly CR, Fischer M, Allegretti JR, LaPlante K, Stewart DB, Limketkai BN, et al. ACG Clinical Guidelines: Prevention, Diagnosis, and Treatment of Clostridioides difficile Infections. Official journal of the American College of Gastroenterology | ACG. 2021;116(6):1124-47. Disponible en: 10.14309/ajg.0000000000001278
Wang JW, Kuo CH, Kuo FC, Wang YK, Hsu WH, Yu FJ, et al. Fecal microbiota transplantation: Review and update. Journal of the Formosan Medical Association. 2019;118:S23-31. Disponible en: 10.1016/j.jfma.2018.08.011
Urbonas T, Ianiro G, Gedgaudas R, Sabanas P, Urba M, Kiudelis V, et al. Fecal Microbiome Transplantation for Recurrent Clostridioides difficile Infection: Treatment Efficacy, Short and Long-term Follow-up Results from Consecutive Case Series. Journal of Gastrointestinal and Liver Diseases. 2021;30(4):470-6. Disponible en: 10.15403/jgld-3800
Kelly CR, Yen EF, Grinspan AM, Kahn SA, Atreja A, Lewis JD, et al. Fecal Microbiota Transplantation Is Highly Effective in Real-World Practice: Initial Results From the FMT National Registry. Gastroenterology. 2021;160(1):183-192.e3. Disponible en: 10.1053/j.gastro.2020.09.038
Shogbesan O, Poudel DR, Victor S, Jehangir A, Fadahunsi O, Shogbesan G, et al. A Systematic Review of the Efficacy and Safety of Fecal Microbiota Transplant for Clostridium difficile Infection in Immunocompromised Patients. Can J Gastroenterol Hepatol. 2018;2018:1394379. Disponible en: 10.1155/2018/1394379
Navalkele BD, Polistico J, Sandhu A, Awali R, Krishna A, Chandramohan S, et al. Clinical outcomes after faecal microbiota transplant by retention enema in both immunocompetent and immunocompromised patients with recurrent Clostridioides difficile infections at an academic medical centre. Journal of Hospital Infection. 2020;106(4):643-8. Disponible en: 10.1016/j.jhin.2020.09.027
Friedman-Korn T, Livovsky DM, Maharshak N, Aviv Cohen N, Paz K, Bar-Gil Shitrit A, et al. Fecal Transplantation for Treatment of Clostridium Difficile Infection in Elderly and Debilitated Patients. Dig Dis Sci. 2018;63(1):198-203. Disponible en: 10.1007/s10620-017-4833-2
Terveer EM, Vendrik KE, Ooijevaar RE, van Lingen E, Boeije-Koppenol E, van Nood E, et al. Faecal microbiota transplantation for Clostridioides difficile infection: Four years’ experience of the Netherlands Donor Feces Bank. United European Gastroenterology Journal. 2020;8(10):1236-47. Disponible en: 10.1177/2050640620957765
Baunwall SMD, Lee MM, Eriksen MK, Mullish BH, Marchesi JR, Dahlerup JF, et al. Faecal microbiota transplantation for recurrent Clostridioides difficile infection: An updated systematic review and meta-analysis. eClinicalMedicine [Internet]. 2020 [citado 17 de septiembre de 2022];29. Disponible en: 10.1016/j.eclinm.2020.100642
Ianiro G, Maida M, Burisch J, Simonelli C, Hold G, Ventimiglia M, et al. Efficacy of different faecal microbiota transplantation protocols for Clostridium difficile infection: A systematic review and meta-analysis. United European Gastroenterol J. 2018;6(8):1232-44. Disponible en: 10.1177/2050640618780762
Cheng YW, Alhaffar D, Saha S, Khanna S, Bohm M, Phelps E, et al. Fecal Microbiota Transplantation Is Safe and Effective in Patients With Clostridioides difficile Infection and Cirrhosis. Clinical Gastroenterology and Hepatology. 2021;19(8):1627-34. Disponible en: 10.1016/j.cgh.2020.06.051
Cammarota G, Masucci L, Ianiro G, Bibbò S, Dinoi G, Costamagna G, et al. Randomised clinical trial: faecal microbiota transplantation by colonoscopy vs. vancomycin for the treatment of recurrent Clostridium difficile infection. Aliment Pharmacol Ther. 2015;41(9):835-43. Disponible en: 10.1111/apt.13144
Kao D, Roach B, Silva M, Beck P, Rioux K, Kaplan GG, et al. Effect of Oral Capsule– vs Colonoscopy-Delivered Fecal Microbiota Transplantation on Recurrent Clostridium difficile Infection: A Randomized Clinical Trial. JAMA. 2017;318(20):1985-93. Disponible en: 10.1001/jama.2017.17077
Perler BK, Chen B, Phelps E, Allegretti JR, Fischer M, Ganapini V, et al. Long-Term Efficacy and Safety of Fecal Microbiota Transplantation for Treatment of Recurrent Clostridioides difficile Infection. Journal of Clinical Gastroenterology. 2020;54(8):701-6. Disponible en: 10.1097/MCG.0000000000001281
Saha S, Mara K, Pardi DS, Khanna S. Durability of Response to Fecal Microbiota Transplantation After Exposure to Risk Factors for Recurrence in Patients With Clostridioides difficile Infection. Clin Infect Dis. 2020;73(7):e1706-12. Disponible en: 10.1093/cid/ciaa1457
Hassoun A, Edwards J. 1122. Evaluation of Fecal Microbiota Transplant (FMT) in Elderly Patients With recurrent Clostridium difficile Infection (CDI). Open Forum Infect Dis. 2018;5(Suppl 1):S336. Disponible en: 10.1093/ofid/ofy210.955
DeFilipp Z, Bloom PP, Torres Soto M, Mansour MK, Sater MRA, Huntley MH, et al. Drug-Resistant E. coli Bacteremia Transmitted by Fecal Microbiota Transplant. New England Journal of Medicine. 2019;381(21):2043-50. Disponible en: https://www.nejm.org/doi/full/10.1056/NEJMoa1910437
Zellmer C, Sater MRA, Huntley MH, Osman M, Olesen SW, Ramakrishna B. Shiga Toxin–Producing Escherichia coli Transmission via Fecal Microbiota Transplant. Clinical Infectious Diseases. 2021;72(11):e876-80. Disponible en: 10.1093/cid/ciaa1486
Wang S, Xu M, Wang W, Cao X, Piao M, Khan S, et al. Systematic Review: Adverse Events of Fecal Microbiota Transplantation. PLoS One. 2016;11(8):e0161174. Disponible en: 10.1371/journal.pone.0161174
Kelly CR, Ihunnah C, Fischer M, Khoruts A, Surawicz C, Afzali A, et al. Fecal Microbiota Transplant for Treatment of Clostridium difficile Infection in Immunocompromised Patients. Am J Gastroenterol. 2014;109(7):1065-71. Disponible en: 10.1038/ajg.2014.133
Ridaura VK, Faith JJ, Rey FE, Cheng J, Duncan AE, Kau AL, et al. Cultured gut microbiota from twins discordant for obesity modulate adiposity and metabolic phenotypes in mice. Science. 2013;341(6150):10.1126/science.1241214. Disponible en: 10.1126/science.1241214
Saffouri G, Pardi D, Kashyap P, Khanna S. Body Mass Index Changes After Fecal Microbiota Transplant for RecurrentClostridium difficileInfection: 216. Official journal of the American College of Gastroenterology | ACG. 2016;111:S103. Disponible en: https://journals.lww.com/ajg/fulltext/2016/10001/body_mass_index_changes_after_fecal_microbiota.216.aspx
Fischer M, Kao D, Kassam Z, Smith J, Louie T, Sipe B, et al. Stool Donor Body Mass Index Does Not Affect Recipient Weight After a Single Fecal Microbiota Transplantation for Clostridium difficile Infection. Clinical Gastroenterology and Hepatology. 2018;16(8):1351-3. Disponible en: https://www.cghjournal.org/article/S1542-3565(17)31448-9/pdf
Khoruts A, Rank KM, Newman KM, Viskocil K, Vaughn BP, Hamilton MJ, et al. Inflammatory Bowel Disease Affects the Outcome of Fecal Microbiota Transplantation for Recurrent Clostridium difficile Infection. Clin Gastroenterol Hepatol. 2016;14(10):1433-8. Disponible en: 10.1016/j.cgh.2016.02.018
Kelly CR, Kahn S, Kashyap P, Laine L, Rubin D, Atreja A, et al. Update on FMT 2015: Indications, Methodologies, Mechanisms and Outlook. Gastroenterology. 2015;149(1):223-37. Disponible en: 10.1016/j.cgh.2016.02.018
Allen J, Sears CL. Impact of the gut microbiome on the genome and epigenome of colon epithelial cells: contributions to colorectal cancer development. Genome Medicine. 2019;11(1):11. Disponible en: https://rdcu.be/c0TDW
Blaser MJ. Fecal Microbiota Transplantation for Dysbiosis — Predictable Risks. N Engl J Med. 2019;381(21):2064-6. Disponible en: 10.1056/NEJMe1913807